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Shining a Light on Xeroderma Pigmentosum
John J. DiGiovanna1 and Kenneth H. Kraemer1
Xeroderma pigmentosum (XP) is a rare, autosomal
recessive disorder of DNA repair characterized by sun
sensitivity and UV radiation–induced skin and mucous
membrane cancers. Initially described in 1874 by
Moriz Kaposi in Vienna, nearly 100 years later, James
Cleaver in San Francisco reported defective DNA
repair in XP cells. This eventually provided the basis
for a mechanistic link between sun exposure, DNA
damage, somatic mutations, and skin cancer. XP cells
were found to have defects in seven of the proteins of
the nucleotide excision repair pathway and in DNA
polymerase Z. XP cells are hypersensitive to killing by
UV radiation, and XP cancers have characteristic ‘‘UV
signature’’ mutations. Clinical studies at the National
Institutes of Health found a nearly 10,000-fold increase
in skin cancer in XP patients under the age of 20 years,
demonstrating the substantial importance of DNA
repair in cancer prevention in the general population.
Approximately 25% of XP patients have progressive
neurological degeneration with progressive loss of
neurons, probably from DNA damage induced by
oxidative metabolism, which kills nondividing cells
in the nervous system. Interestingly, patients with
another disorder, trichothiodystrophy, have defects in
some of the same genes as XP, but they have primary
developmental abnormalities without an increase in
skin cancer.
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PROLOGUE FABLE
Imagine it’s the late 1800s. An infant is taken outside on
the first sunny day of spring. After a short time, the child
becomes irritable and starts crying. By the next morning,
her skin becomes very red and blistered with eyes swollen
shut. Parents wonder what sort of malady this could be?
Slowly the skin and eyes heal. But it happens again and
again. Strong sunlight seems to bother her eyes that are
often red and watering. Just past her first birthday, her skin
starts to develop freckle-like spots, mostly in areas not
covered by clothing. In older childhood growths develop
and turn into tumors that seem to eat through her skin. She
doesn’t always respond when called as if she were
becoming deaf, she is having more difficulty walking
and her thinking has become quite slow.
We now know xeroderma pigmentosum (XP) as a rare
autosomal recessive disorder of DNA repair, which manifests
clinically as photosensitivity, actinic damage to the skin,
cancer of UV radiation–exposed areas of the skin and mucous
membranes of the eyes and mouth, and, in some patients,
progressive neurological degeneration (Table 1). The skin
is normal at birth and the disorder may present in two
different ways. Some patients have an exaggerated response
to UV radiation exposure with pronounced burning
and blistering on minimal exposure to sunlight (Figure 1a).
Others have a normal acute response to sun expo-
sure. However, they all develop freckle-like pigmentary
changes in sun-exposed areas, which eventually appear as
poikiloderma (hyperpigmentation, hypopigmentation, atro-
phy, and telangiectasias). Unlike children in the general
population, this freckling (lentiginous hyperpigmentation)
typically appears before the age of 2 years (Figure 1b).
The average age at onset of first skin cancer is o10 years
(Figure 2a).
Our evolving understanding of the puzzling clinical
findings of XP have raised many questions related to cell
biology, photobiology, photocarcinogenesis, neurodegenera-
tion, and genome stability. Answering the questions has
illuminated several areas of biology, but there are still many
yet to be clarified.
HISTORY OF XP
The road to our current understanding of XP started in the late
nineteenth century with Moriz Kaposi, the Hungarian-born
professor of dermatology in Vienna. In 1874, Kaposi
described four patients with xeroderma or ‘‘parchment skin’’
in the early textbook of dermatology (Hebra and Kaposi,
1874), which he wrote with Professor Ferdinand Hebra,
his father-in-law (Kraemer et al., 1987). ‘‘In addition to the
parchment-like dryness, thinness, and wrinkling of the
epidermis, the checkered pigmentation, and the small
dilatations of the vessels, the most remarkable symptoms
were the contraction and, at the same time, thinning of the
skin’’, features designating poikiloderma. His description
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distinguishes the pigmented lesions from normal as ‘‘dark
brown, pigmented spots resembling those of freckles,’’
recognizing the clinical distinction between freckles and
clinically atypical pigmented lesions (e.g., lentigines; Figure
1b, c, d, and f). He notes (as in Figure 1f) that the ‘‘condition
of the skin ceased with an abrupt line of demarcation’’ at
the upper third of the arm,’’ but does not postulate why.
He mentions the occurrence of a pear-shaped, red, granulat-
ing, fissured tumor that had developed within 1 year, and
states ‘‘We recognised the growth to be an epithelioma, and
destroyed it in great part.’’ However, his puzzlement was
evidenced by his statement ‘‘I have no more to say respecting
this peculiar diseasey’’
In 1883, Albert Neisser of Breslau, Germany, reported
XP with neurological abnormalities in two siblings who had
XP with progressive neurological degeneration beginning in
the second decade (Neisser, 1883). At present, it is recog-
nized thatB25% of XP patients in the United States develop
progressive neurological degeneration (Bradford et al., 2011;
Table 1 and Figure 1d).
In 1878, RW Taylor, MD, of New York reported the first
few XP patients in the United States at the inaugural meeting
Table 1. Comparison of features of XP, TTD, and CS
Feature
Xeroderma
pigmentosum (XP)
XP with neurological
abnormalities
Trichothio-
dystrophy (TTD)
Cockayne
syndrome (CS)
XP/CS
complex
Skin
Skin sun sensitivity Yes Severe Yes/no Yes Yes
Lentiginous skin pigmentation Yes Yes No No Yes
Sunlight-induced skin cancer Yes Yes No No Yes
Eyes
Photophobia Yes Yes Yes/no Yes Yes
Conjunctival growths Yes Yes No No Yes
Cancer (anterior eye/lids) Yes Yes No No Not reported
Congenital cataracts No No Yes Yes No
Pigmentary retinal degeneration No No No Yes Yes
Somatic
Short stature No No/yes Yes Yes Yes
Immature sexual development No No No/yes Yes Yes
Nervous system
Progressive sensorineural deafness No Yes No Yes Yes
Developmental delay No Yes Yes Yes Yes
Progressive neurological degeneration No Yes Unknown Yes Yes
Primary neuronal degeneration No Yes No No No
Dysmyelination of brain No No Yes Yes Yes
Cerebral atrophy No Yes No/yes Yes Yes
Cerebellar atrophy No Yes No Yes Yes
Calcification (basal ganglia) No No No/yes Yes Yes
Disease mechanism
Reaction to exogenous or endogenous
DNA-damaging agents
Yes—severe Yes—severe No Yes Yes
Developmental defect No Yes Yes—severe Yes—severe Yes—severe
Nucleotide excision repair defect Yes Yes Yes Yes Yes
Molecular defects XPA, XPC, XPD, XPE, XPF,
XPG, XP VARIANT (POLH)
XPA, XPB, XPD,
XPF, XPG
XPB, XPD, TTDA,
TTDN1
CSA, CSB XPB, XPD,
XPG
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of the American Dermatological Association. In 1888, he
reviewed the world literature and reported a total of 40 cases
(Taylor, 1888).
The state of understanding of the disease was proposed in
a 1926 report as follows (Per, 1926):
(1) ‘‘Xeroderma pigmentosum is due to an extreme sensi-
tization of the skin to ultra-violet rays of the sun.
(2) This congenital insufficient resistance of the skin to the
actinic rays seems to be dependent on the consanguinity
of the parents.
(3) Photodynamic substances in the organism (haemato-
porphyrin) do not play any part in the pathogenesis of
this disease.
(4) The actinic rays of the sun produce an unquestionably
unfavourable influence on the course of xeroderma
pigmentosum.
(5) Medical preventive measures have a high value in this
disease.’’
Per also states: ‘‘However, notwithstanding detailed
pathological studies of the diseasey no one has
succeeded in making clear the obscure pathogenesis of
this disease.’’
In 1932, de Sanctis and Cacchione described three
brothers in the same family with features of XP, mental
deficiency, dwarfism, and gonadal hypoplasia with progres-
sive neurological degeneration beginning at 2 years of age
Figure 1. Xeroderma pigmentosum (XP) and trichothiodystrophy (TTD) patients studied. (a) Patient XP420BE complementation group X-PD at 9 months
of age with severe blistering erythema of the malar area following minimal sun exposure. Note sparing of her forehead and eyes that were protected by a hat.
(b) Patient XP358BE (XP-C) at the age of 2 years did not sunburn easily but developed multiple hyperpigmented macules on her face. A rapidly growing
squamous cell carcinoma (SCC) or keratoacanthoma grew on her upper lip and a precancerous lesion appeared on her forehead. (c) Northern African
patient XP393BE (XP-C; Mahindra et al., 2008) at the age of 23 years with numerous hyperpigmented macules on his face. Nodular basal cell cancer is present
on his left nasal root. Pigmented basal cell cancer is present on his left cheek. His eyes show cornea scarring from unprotected sun exposure. (d) Patient
XP19BE (XP-A; Robbins et al., 1991) at the age of 35 years with neurological degeneration. He has numerous hyperpigmented macules on sun-exposed areas of
his face and neck. Progressive sensorineural deafness requires the use of a hearing aid. Images a–d are from Bradford et al. (2011). (e) Corneal clouding,
pterygium, contact lens, and loss of lashes on lower eyelid. (f) Sharp demarcation between the poikilodermatous changes seen in sun-exposed skin compared
with double-covered area of the buttocks of a 35-year-old XP patient. (g) Loss of vermillion border of the lips with prominent telangiectasias and scaring
of the lips and anterior tongue. (h) SCC of the anterior tongue in an African man (from Mahindra et al., 2008). (i, j) Clinical appearance of TTD. (i) A 3-year-old
girl with short brittle hair, which is sparse and broken off at different lengths. She rarely has haircuts, except to trim uneven areas. She has a smiling, outgoing
personality typical of TTD. (j) Tiger-tail banding under polarizing microscopy (original magnification  10). Images i and j are from Liang et al. (2005).
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(de Sanctis and Cacchione, 1932). This severe phenotype is
not commonly observed.
XP was described in a black African in 1938 (Loewenthal
and Trowell, 1938; Figure 1c) and in an American black in
1940 (King and Hamilton, 1940).
Gartler reported UV radiation hypersensitivity of XP cells
in 1964 (Gartler, 1964), but the importance of this report was
not recognized for years. DNA repair abnormalities in XP
were brought to the attention of the general scientific
community by Cleaver’s report in 1968 describing deficient
excision repair in cultured skin fibroblasts (Cleaver, 1968).
Stable DNA photoproducts were identified by Setlow (Setlow
and Setlow, 1962). These photoproducts were not removed
by XP cells (Setlow et al., 1969; Cleaver and Trosko, 1970).
XP cells were reported to be defective in the excision repair
pathway by which UV radiation damage to DNA is repaired
in vitro (Reed et al., 1969) and also in vivo (Epstein et al.,
1970). The excision repair-proficient form of XP was
described in 1971 (Burk et al., 1971) and subsequently
named ‘‘XP Variant’’ (Cleaver, 1972). Cell fusions studies
(1972) demonstrated heterogeneity of the XP molecular
defects (De Weerd-Kastelein et al., 1972). Fusion of
fibroblasts from different XP patients to form heterokaryons
(a cell with nuclei from different patients) was found to
exhibit correction (complementation) of the defective repair.
To correct the defect, the different nuclei supplied what the
other was lacking. This implied that different cells had
different defects and led to the characterization of different
complementation groups A through G (Kraemer et al.,
1975a, b; Arase et al., 1979; Keijzer et al., 1979; Figures 3
and 4). Two decades of research and advances in molecular
biology, including generation of rodent cell complementation
groups and yeast mutants, finally yielded the genes respon-
sible for the different complementation groups: XPA (Tanaka
et al., 1990), XPB/ERCC3 (Weeda et al., 1990a b), XPC
(Legerski and Peterson, 1992), XPD/ERCC2 (Flejter et al.,
1992a b), XPE/DDB2 (Dualan et al., 1995), XPF/ERCC4
(Sijbers et al., 1996), XPG/ERCC5 (Mudgett and MacInnes,
1990), and XP VARIANT (polymerase Z; Johnson et al., 1999;
Masutani et al., 1999; Figures 3 and 4 and Table 1).
WHAT HAVE WE LEARNED ABOUT XP AND WHAT HAS
XP TAUGHT US ABOUT BASIC BIOLOGY?
Relationship of sun exposure to skin cancer
Epidemiological studies in the normal population have been
used as evidence to support a role for sunlight as a cause of
skin cancer. For example, a higher frequency of skin cancer
has been reported in (1) Caucasians with light-colored
skin and eyes and frequent sunburns, (2) individuals with
large outdoor exposures such as sunbathers and outdoor
laborers, (3) association with latitudes closer to the equator,
and (4) exposed areas of the body compared with covered
areas. However, this relationship is most clearly and power-
fully demonstrated in XP patients, where UV radiation
damage leads to an early onset and increased frequency of
both nonmelanoma skin cancer (NMSC) and melanoma.
In XP patients, the median age of first NMSC was 9 years
(Bradford et al., 2011) compared with 67 years in the general
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Figure 2. Xeroderma pigmentosum (XP) skin cancer by age at first skin cancer diagnosis and skin cancer type and mortality compared with the
US general population. (a) Proportion of nonmelanoma skin cancer (NMSC) patients diagnosed at selected ages. (b) Proportion of melanoma patients
diagnosed at selected ages. XP individuals with both NMSC and melanoma were used for both analyses. General population data taken from Glass and Hoover
(1989). (c) Kaplan–Meier curve of XP patient survival compared with the US general population: 30% of XP patients had died by the age of 32 years. The survival
of the XP patients was significantly less than the general population (Po0.001). (d) Kaplan–Meier curve of XP patient survival stratified by neurological
phenotype. Patients with neurological degeneration had poorer survival rates than those without neurological degeneration (P¼ 0.04). Graphs are from Bradford
et al. (2011).
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population (Figure 2a). Similarly, the median age at onset of
the first XP melanoma was 22 years, compared with 55 years
in the general population (Figure 2b). This highlights the
profound role of an intact DNA repair system in providing
protection against skin cancer, in effect, giving the average
Caucasian individual more than half a century delay in the
onset of skin cancer.
XP patients can develop hundreds of skin cancers.
Compared with the general population, XP patients under
the age of 20 years have a 10,000-fold increase in the
frequency of NMSC, a 2,000-fold increase in melanomas, a
1,000-fold increase in cancer of the sun-exposed tissues of
the eye, and a 100,000-fold increase in tongue cancers
(Kraemer et al., 1994; Bradford et al., 2011). The anatomic
distribution of NMSC in XP patients is similar to that in the
general population, with over 80% occurring on the face,
head, and neck (Kraemer et al., 1994). The distribution of
melanomas is different from that of NMSC in XP patients
and in the general population. Melanoma occurs more
commonly on the extremities, and in both groups 445% of
melanomas were found on the extremities. This suggests that
there are different mechanisms involved in the generation of
melanoma versus NMSC. The similarity of the distribution of
both melanomas and NMSC in both groups suggests that the
mechanism of carcinogenesis in XP patients mirrors that in
the general population. However, the reversal in median age
at onset of NMSC and melanomas in XP patients (9 and
22 years) in comparison with the general population (67 and
55 years; Figure 2a and b) points to a greater role of sun
exposure/DNA repair in the induction of NMSC.
The UV radiation–exposed areas of the skin, tongue, and
eye have a high cancer risk (Figure 1c, e, g, and h). Although
there is an increased risk to the anterior portion of the eye
(Ramkumar et al., 2011), the lens is a barrier to UV radiation
penetration and acts as protection to deeper eye structures.
Similarly, the UV radiation–exposed areas of the lips and
tongue have an increased cancer risk compared with deeper,
more shielded mucous membrane surfaces. The observation
that covered areas of the skin and other tissues are highly
protected in XP patients (Figure 1f), with lower cancer
frequencies, demonstrates the benefit of UV radiation
protection in the prevention of sun-induced malignancy.
XP patients under the age of 20 years have an B50-fold
increase in cancers of the brain and other organs of the
XPF TTDA
RPA
XPA
XPA
ERCC1
XPG
XPF
Global genome repair (GGR) Transcription coupled repair (TCR)
Damage
recognition
DNA excision
and de novo
synthesis
DNA
unwinding
TFIIH
TTDA XPD
XPB
XPF
XPD
XPB
XP
HHR23B
XPC
XPA
RPA
XPG
XPG
XPG
Incision
XPC
XPE
CSBCSA
DNA pol ε/δ
PCNA, RF-C
RPA
DNA ligase I
RNAPII
CSB
RPA
XPA
ERCC1
ERCC1
CPD
6-4 PP
DNA
lesion
DNA
lesion
CSA
Figure 3. Nucleotide excision repair (NER) pathway. Transcription-coupled repair (TCR) removes damage from actively transcribed genes, whereas
global genome repair (GGR) removes damage from the remainder of the genome. In GGR, damage such as UV radiation–induced cyclobutane pyrimidine
dimers (CPDs) or 6-4 photoproducts (6-4 PPs) is recognized by proteins including the XPE (DDB2) and XPC gene products. In TCR, the lesion appears
to block the progress of RNA polymerase II in a process involving the CSA and CSB gene products. Following initial damage recognition, the pathways
converge. The XPB (ERCC3) and XPD (ERCC2) helicases unwind the region surrounding the lesion along with the XPA and XPG (ERCC5) gene products,
and replication protein A (RPA). The XPF and XPG (ERCC5) endonucleases perform incisions to remove the lesion in a fragment of B30 nucleotides.
The resulting gap is filled in by de novo DNA synthesis. This system is coordinated so that if one part of the pathway is mutated the entire pathway fails to
function normally. Mutations in the genes in rectangles have been associated with clinical disease. This diagram is modified from Van Steeg and Kraemer
(1999) and Kraemer et al. (2007). PCNA, proliferating cell nuclear antigen; RF-C, replication factor-C.
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central nervous system (Kraemer et al., 1994). These include
brain medulloblastoma (Giannelli et al., 1981), glioblastoma,
spinal cord astrocytoma (DiGiovanna et al., 1998), and
Schwannoma. These are not sunlight-exposed tissues and the
relationship of these cancers to DNA damage is not known.
On the other hand, carcinogens in cigarette smoke bind to
DNA and cause the type of damage that would be repaired by
the nucleotide excision repair (NER) system in normal cells
(Maher et al., 1977, 1987). Thus, XP patients are at greater
risk of smoking-induced cancer. A 34-year-old smoker with
XP died of lung cancer (Kraemer et al., 1994). In a study of
106 XP patients followed up at the National Institutes of
Health for almost 4 decades, the median age at death of the
XP patients was 32 years, a significant reduction compared
with the general population (Figure 2c; Bradford et al., 2011).
The median age at death of XP patients with neurological
degeneration (29 years) was younger than those patients who
had no neurological degeneration (37 years; Figure 2d).
Neurological degeneration was second only to cancer in
cause of death in XP patients.
Role of sun burning in the development of UV
radiation–induced skin damage and skin cancer
Studies in the general population have dissociated the
role of acute burning versus chronic lower exposures in the
causation of skin cancer. The chronic exposure of light-
skinned, outdoor workers has been associated with the
development of multiple basal cell carcinomas and squa-
mous cell carcinomas. In contrast, acute blistering burns in
childhood have been implicated as a cause of melanoma.
However, experience with XP demonstrates that this relation-
ship is more complex. XP typically presents as either of two
diverse clinical scenarios. A young child aged 1 to 2 years
can develop an alarming blistering or oozing eruption after
a short time outdoors in a relatively shady environment
(Figure 1a). The onset of the eruption may be delayed for a
day or so and may be misdiagnosed as impetigo. After
repeated occurrences, the parents learn to rigorously protect
the child. Other children with XP do not burn after minimal
sun exposure (Figure 1b). However, most XP patients do
develop early-onset freckling before the age of 2 years. XP
children who do not burn but only freckle may not pay
attention to rigorous sun avoidance and paradoxically may
experience extensive sun exposure and often develop skin
cancers in early childhood (Bradford et al., 2011). It is
somewhat surprising that, in the general population, blister-
ing burns are associated with earlier onset of melanoma,
whereas in XP this is reversed. XP patients who never burned
on minimal sun exposure were found to be significantly more
likely to develop skin cancer at an earlier age than those who
always or sometimes burned on minimal sun exposure
(Bradford et al., 2011).
XP patients with defects in complementation groups A, B,
D, and G tend to have blistering burns on minimal sun
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A total of 10 clinical diseases and 13 molecular defects are represented. One disease may be caused by mutations in several different genes.
Conversely, different mutations in one gene may result in several different clinical diseases. Modified from Kraemer (2004) and Kraemer et al. (2007).
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exposure, whereas those in groups C, E, and variant do not
(Figures 3 and 4 and Table 1). However, all are at high risk
of developing early-onset freckling, lentigines, and skin
cancers. These observations dissociate the acute burning
from the mechanism of UV radiation carcinogenesis and raise
important unanswered questions about how the different
abnormalities of DNA repair lead to increased cancer risk in
all patients, but acute photosensitivity in only some patients.
Clearly, the inflammatory reaction of acute burning is not
necessary for the development of skin cancer in XP patients.
A model of photoaging?
Photoaging, or dermatoheliosis, describes changes to the
skin from chronic exposure to the sun or UV radiation. This
includes pigmentary changes and alterations in texture and
color. Early damage to melanocytes appears as freckling (tan,
symmetrical, round macules) and later as lentigines (colored
variable intensity of brown with irregular shapes, sizes, and
borders). In contrast, solar elastosis gives the skin a bumpy,
yellowed appearance and is thought to be secondary to
damage to structural components of the dermis including
elastic and collagen fibers. Telangiectasias are the vascular
components of UV radiation damage, and atrophy becomes
noticeable when the full spectrum of poikilodermatous
changes is present. These changes are common in the sun-
exposed areas of light-skinned Caucasians in the general
population who have sustained excessive, chronic UV
radiation damage, where skin laxity, sagging, and wrinkles
are prominent. In contrast, although patients with XP develop
freckling at an early age, followed by the development of
large numbers of lentigos and telangiectasias, they do not
develop the skin laxity, sagging, wrinkles, or cutis rhomboi-
dalis of the posterior neck. As described by Kaposi in 1874
(Hebra and Kaposi, 1874), they actually develop skin
tightening—the opposite of wrinkling. This contrast dissoci-
ates the mechanisms causing the pigmentary and vascular
changes (DNA damage in the epidermis and upper dermis)
from the causes of damage to structural components of dermal
elastic and collagen fibers. This may be explained in part by
the absorption of shorter-wavelength, DNA damaging, UVB
by the epidermis, and greater penetration of UVA into the
deeper dermis with a direct damaging effect on protein. The
degree of elastosis may serve as a ‘‘dosimeter’’ of the amount
of UV radiation reaching the dermis (Robbins et al., 1974).
Thus, XP patients demonstrate severe epidermal changes with
minimal UV radiation exposure to the proteins in the dermis
because of their defective repair of epidermal DNA damage.
A model for clinical research: chemoprevention of skin cancers
Because of the high frequency of skin cancers in XP patients
and the associated morbidity, effective chemoprevention
approaches would convey enormous benefit. In fact, XP has
been used as a model for skin cancer chemoprevention
studies. As each patient may develop large numbers of new
skin cancers, significant differences may be observed with
small numbers of patients. A trial of oral isotretinon
conducted with only seven XP patients demonstrated a
statistically significant (63%) reduction in new skin cancers
compared with the 2-year interval before treatment (Kraemer
et al., 1988). This controlled clinical trial was one of the first
to conclusively demonstrate effective chemoprevention of
any cancer in humans. At present, isotretinoin and the related
retinoid acitretin are widely used in patients at high risk of
developing new skin cancers who have other predisposing
conditions including post-transplantation and the NBCC
syndrome. T4 endonuclease V, a bacterial DNA repair
enzyme, was also tested in a double-blind study of 20 XP
patients and was found to lower the rate of actinic keratoses
and basal cell carcinoma (Yarosh et al., 2001).
Specificity in sensitivity to damaging agents
One of the lessons learned from XP is that patient
hypersensitivity to damaging agents is specific. Although XP
cells are hypersensitive to killing by UV irradiation, they have
normal killing after X-rays. In normal cells, the bulky DNA
damage caused by UV radiation is repaired by the NER
system, which is defective in XP patients (Figure 3). Most of
the X-ray damage is different and the X-ray repair systems are
normal in XP cells. In fact, patients with XP who develop
inoperable eye or internal tumors such as brain or spinal cord
tumors have been treated with high-dose X-irradiation as
therapy and have tolerated the treatment well (Grier, 1919;
Giannelli et al., 1981; DiGiovanna et al., 1998). This is in
contrast to patients who are hypersensitive to X-irradiation,
such as patients with the NBCC syndrome. NBCC patients
have a germline mutation in the PATCH gene, and their cells
retain only one of the two normally present functional alleles.
Basal cell carcinomas result when NBCC cells sustain a
second hit, which can be the result of X-irradiation. NBCC
patients who develop neuroblastoma at a young age and
receive treatment with radiation therapy frequently develop a
large number of basal cell carcinomas in the radiation port,
where they may also be at risk for development of additional
central nervous system tumors (Kleinerman, 2009). These
observations clearly highlight the differences in the mechan-
isms of repair of UV irradiation-induced versus X-irradiation-
induced DNA damage.
DNA repair—molecular mechanisms of carcinogenesis
The skin of XP patients is hypersensitive to sun exposure, and
this is reflected in a hypersensitivity of cultured skin
fibroblasts following exposure to UV radiation (Ruenger
et al., 2008; Kraemer and Ruenger, 2008). Thus, examination
of cultured cells from XP patients provides an opportunity to
obtain insights into detailed mechanism of the relationship of
UV radiation damage to carcinogenesis. For example, cells
from XP patients are hypersensitive to killing by UV radiation
and by UV radiation–mimetic chemical compounds such as
benzo-a-pyrene in cigarette smoke (Maher et al., 1977, 1987;
Kraemer and Ruenger, 2008). In addition, XP cells are
hypermutable following UV radiation exposure, thereby
linking sun exposure to somatic mutations.
UV radiation exposure of DNA produces several types of
stable dipyrimidine nucleotide photoproducts (Kraemer and
Ruenger, 2008). The major photoproduct is the cyclobutane
pyrimidine dimer of adjacent thymines (T), cytosines (C), or
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mixed T and C. Also formed are 6-4 pyrimidine-pyrimodone
TC photoproducts (6-4PPs). These DNA lesions serve as
substrates for the nucleotide excision repair pathway
(Figure 3). In normal cells, the DNA-distorting 6-4PPs are
repaired more rapidly (within 6 hours) than the cyclobutane
pyrimidine dimer (B50% removed by 12 hours). Neither
photoproduct is repaired by XP cells. Unrepaired photo-
products are premutagenic lesions. During replication, a
DNA polymerase meeting an unrepaired photoproduct can
stop replication—leading to cell death. As the photoproduct
distorts the nucleotides, they do not code properly. Poly-
merases that bypass the photoproducts frequently incorporate
the incorrect nucleotide (e.g., incorporating a T in place of a
C that is involved in a TC photoproduct; Lange et al., 2011).
This leads to a C-to-T mutation, which is characteristic of UV
radiation mutagenesis. In cultured XP cells and UV radia-
tion–treated plasmids grown in XP cells, these C-to-T or
CC-to-TT ‘‘UV signature mutations’’ are frequently found
after UV radiation exposure (Bredberg et al., 1986; Gozukara
et al., 1994).
If purified plasmid DNA is exposed to UV radiation and
transfected (introduced) into cells, the plasmid DNA is
subject to repair by the DNA repair processes of the cell.
The efficiency of repair can be assessed by the use of a
plasmid that codes for a marker gene. The DNA damage in
the plasmid can be measured or modified before introduction
into the cells and then the effect can be measured (Emmert
et al., 2002). We used this assay to demonstrate that one UV
radiation photoproduct in the coding strand of the marker
gene was sufficient to block its transcription in sensitive XP
cells (Protic-Sabljic and Kraemer, 1985), thereby demonstrat-
ing the importance of DNA repair in removal of DNA damage
that blocks transcription. Similarly, replicating plasmid
coding for a suppressor transfer RNA marker that is assessed
in bacteria revealed that the XP cells introduce a high
frequency of mutations into the plasmids. Sequence analysis
of the recovered plasmids showed that the mutations
following UV radiation exposure of the plasmid are
frequently at sites of dipyrimidine photoproducts and lead
to C-to-T mutations (Bredberg et al., 1986). This is strong
direct evidence of the role of UV radiation in mutagenesis.
These cellular studies have provided a molecular foundation
for demonstration of the UV radiation–induced origin of
mutations found in NMSC (Giglia et al., 1998; Couve-Privat
et al., 2004) and melanomas (Daya-Grosjean and Sarasin,
2005; Wang et al., 2009) in cancer-suppressing genes (p53,
PTCH, and PTEN) in XP patients. This CC-to-TT UV radiation
‘‘signature’’ has been used to link sun exposure to mutations
in many other cancer-related genes in melanomas and other
skin cancers in the general population (Prickett et al., 2009;
Pleasance et al., 2010; Wei et al., 2011).
XP cells are defective in NER (Figure 3; Van Steeg and
Kraemer, 1999). This system serves to recognize DNA
damage, excise the damage, and replace the damaged region
with undamaged DNA. Global genome repair serves to
identify DNA damage in the 99% of the DNA that is not
involved in transcription. Transcription-coupled repair (TCR)
is triggered by a stalled RNA polymerase that contacts DNA
damage in actively transcribed genes comprising the remain-
ing 1% of the DNA. DNA photoproducts in the global
genome are recognized by several proteins acting in tandem,
including double-strand DNA–binding protein 2 (DDB2) and
XPC. TCR-related proteins include Cockayne syndrome A
and B. After recognition, the DNA is unwound by XPB and
XPD helicases, which are part of the 10-subunit basal TFIIH
(transcription factor IIH). These proteins are thus involved in
both DNA repair and transcription of many other genes.
The XPA protein maintains the open DNA region containing
the damage, which is then cut out by XPF/ERCC1 and XPG
endonucleases as part of an B30-nucleotide single-stranded
fragment. The resulting gap is filled in by DNA polymerase
and ligase. The TCR pathway acts more rapidly than the
global genome repair pathway and in fact shows strand-
specific repair with preferential repair of the transcribed
strand. The NER pathway is closely coordinated so that if one
of the proteins is defective, the entire pathway does not
function correctly. Thus, mutations in any of the above
proteins lead to clinical diseases (Figures 3 and 4). The ‘‘XP
variant’’ form of XP has normal NER. These patients have
clinical XP with increased skin cancer susceptibility. Their
cells are deficient in an error-prone DNA polymerase,
polymerase Z, which normally serves to permit DNA
replication past unrepaired photoproducts. Identification of
this class of bypass polymerases provides insights into the
varied mechanisms that organisms have developed to cope
with DNA damage (Lange et al., 2011).
XP neurological degeneration
Approximately 25% of the XP patients have progressive
neurological degeneration (Bradford et al., 2011). These
patients often have defects in the XPA, XPB, XPD, or XPG
genes (Table 1 and Figure 4). They are usually born with
normal size and weight. The earliest clinical abnormalities
are frequently absent deep tendon reflexes and high-
frequency hearing loss, and these can act as screening tests.
Affected individuals may have delayed developmental
milestones. The age at onset and rate of progression of the
neurological abnormalities is variable among patients.
Typical involvement includes sensorineural hearing loss,
progressive intellectual impairment, which may progress in
severe cases to slurred speech, loss of ability to walk,
difficulty in swallowing, and requirement for the use of a
feeding gastrostomy. Imaging studies show thinning of the
cortex of the brain with concomitant dilation of the
ventricles, and thickening of the skull bones. The pathology
is a primary neuronal degeneration without evidence of
inflammation or infiltration by other cells. XP patients with
neurological degeneration have a high mortality (Figure 2d;
Bradford et al., 2011).
Relationships within the family of DNA repair disorders
There are three related, clinically defined disorders of DNA
repair that can be used as archetypes to understand the
spectrum of genotype–phenotype relationships within this
group (Table 1 and Figure 4; Kraemer et al., 2007).
Photosensitivity, neurological/developmental abnormalities,
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and skin cancer are important pathological features that can
be used to distinguish between these three archetypes:
XP, trichothiodystrophy (TTD), and Cockayne syndrome
(CS). In addition, there are several related or overlapping
disorders with similar features that form a family of
syndromes involving neural, oncologic, cutaneous, develop-
mental, and other abnormalities. Table 1 lists detailed clinical
features that may be useful in distinguishing between XP, XP
with neurological disease, TTD, CS, and XP/CS complex.
Although photophobia and skin sun sensitivity may be seen in
all of these conditions, lentiginous hyperpigmentation is seen
in XP but not in TTD or CS. Pigmentary retinal degeneration is
seen in CS, but not in XP or TTD. More precise clinical
delineation has permitted the identification of subtle overlap
syndromes in patients with features of two of these disorders.
Figure 4 diagrams the current state of the evolving geno-
type–phenotype relationships within this group. Phenotypes
representing the clinical disorders are shown in light blue
and molecular defects are shown in gray, with the over-
lapping patterns showing the underlying molecular defect
identified in patients within each phenotypic group. XP can
be diagnosed on the basis of clinical criteria based on the
presence of acute burning on minimal sun exposure, early-
onset freckling before the age of 2 years, and skin cancer.
Although XP patients usually do not have developmental
abnormalities, B25% of XP patients develop progressive
neurological degeneration. TTD is a disorder characterized
by short, brittle hair and multisystem abnormalities (Figure
1i–l). TTD developmental abnormalities may be evident in
the pregnant mother carrying a TTD-affected fetus. These
pregnancy abnormalities may include abnormal triple screen
test results, preterm delivery, preeclampsia, placental ab-
normalities, or HELLP syndrome (Moslehi et al., 2010;
Tamura et al., 2011). The newborn may present with a
collodion membrane, short stature, micrognathia, and have
increased risk of infections, growth and developmental delay,
congenital cataracts, and other abnormalities. Although
patients frequently have photosensitivity, they do not develop
skin cancer or the freckle-like pigmentary abnormalities of
XP. In contrast to XP, the neurological involvement in TTD
patients is usually not one of progressive decline. CS has
features of both disorders with photosensitivity and both
developmental delay and progressive growth and neurologic
decline, but not skin cancer. Cerebro-oculo-facial-skeletal
syndrome is a severe variant of CS, with abnormalities
beginning in utero. Infants are born with contractures
(arthrogryposis), thought to be due to decreased fetal move-
ment, extreme microcephaly, congenital cataracts, and facial
dysmorphism (Laugel et al., 2008, 2010). Careful and precise
assessment of clinical features of each disorder has led to the
identification of patients with several overlap syndromes.
Patients with XP/TTD have features of both diseases, although
mildly attenuated. They have tiger-tail banding and hair shaft
defects, but less prominent than those that occur in TTD,
leading to longer hair. They are at risk for skin and possibly
internal malignancies, but at a lower frequency than seen
in XP. Similarly, overlap syndromes of XP/CS, CS/TTD,
and cerebral-ocular-facial-skeletal syndrome (COFS)/TTD
have been described (Figure 4). Different mutations in the
XPD gene have led to the greatest heterogeneity in clinical
phenotype. Patients with the rare UV-sensitive syndrome
have mild photosensitivity without pigmentary abnormalities
or apparent defects in the central nervous system (Itoh et al.,
1996). Their cells have the same transcription defects as CS
cells and have been reported to have defects in the CSA or
CSB genes (Horibata et al., 2004; Nardo et al., 2009;
Figure 4). This suggests that the defect in the central nervous
system in CS patients may be related to an additional property
of the CS proteins.
HOW HAS XP HELPED US UNDERSTAND THE BASIC
BIOLOGY AND MECHANISMS UNDERLYING OTHER
DISEASES?
When the genes that are defective in XP patients were
identified, the homologous genes were soon identified in
mice. Knockout mice with many of these defects have been
generated (see Mouse Mutation Database v5 at http://
pathcuric1.swmed.edu/Research/research.htm) and serve as
models for probing the role of these genes in carcinogenesis.
For example, mice with defects in XPA and XPC have
increased susceptibility to UV radiation–induced skin cancer
(deVries et al., 1995; Sands et al., 1995; Cheo et al., 2000;
Tanaka et al., 2001). XP heterozygous mice also have an
increase in cancers of both the skin and internal organs (Cheo
et al., 2000). This suggests that humans who are heterozygous
for XP disease–causing mutations—such as 1 million Japanese
people who are carriers of an XPA founder mutation (Hirai
et al., 2006)—may be at increased cancer risk. However,
mice are not perfect models for these diseases as TTD and CS
patients do not have increased skin cancer susceptibility, but
mice with TTD and CS mutations do have increased post-UV
radiation cancer frequency (van der Horst et al., 2002).
Single-nucleotide polymorphisms are variants in the DNA
sequence that occur with a frequency of at least 1% in the
general population. Single-nucleotide polymorphisms may
affect gene function, or, more commonly, act as markers of
genetic differences to which they are linked elsewhere in the
genome. A polyA-T polymorphism in intron 9 of the XPC
DNA repair gene was found to be linked to an A-to-C single-
nucleotide polymorphism in exon 15 that changed amino
acid 939 from Lysine (AAA) to Glutamine (CAA) but did not
alter the XPC function (Khan et al., 2000). The polyA-T
polymorphism was also linked to an XPC intron 11 –5C/A
single-nucleotide polymorphism that altered the frequency of
alternatively spliced XPC mRNA, which was shown to have
reduced DNA repair ability (Khan et al., 2002). This XPC
polyA-T polymorphism was associated with increased sus-
ceptibility to head and neck squamous cell carcinoma (Shen
et al., 2001) and to cutaneous melanoma (Blankenburg et al.,
2005). The use of polymorphisms in the XPD (ERCC2) DNA
repair gene as an indication of cancer susceptibility has been
questioned (Clarkson and Wood, 2005). However, recent
meta-analysis of 13 case–control studies of bladder cancer
(Stern et al., 2009) and 56 case–control studies of several types
of cancer (Wang et al., 2008) found a weak but consistent
association with several polymorphisms in the XPD gene.
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Interestingly, wild type rodent cells have normal post-UV
radiation survival despite an apparent defect in NER as
indicated by some DNA repair assays. These cells have a
defect in the DDB2 NER gene in the dermis with defective
global genome repair but normal TCR. A ‘‘humanized’’
mouse was developed that had addition of the DDB2
gene, and it showed increased DNA repair (Alekseev et al.,
2005). Interestingly, mouse keratinocytes have a higher level
of DDB2 and greater repair than fibroblasts (Pines et al.,
2009).
Although patients with defects in some of the NER genes
show profound, progressive neurological abnormalities, mice
with defects in XPA or CS do not. However, crossing of Xpa
or Xpc mice with Csb mice does result in mice with severe
neurological abnormalities (Murai et al., 2001; Laposa et al.,
2007). The XPG mutant mouse does show neurological
abnormalities. These mouse model systems have been used
to mimic some features of neurological degeneration in the
general population. A major theory of neurodegeneration
involves generation of free radicals by oxidative processes
involving the mitochondria. These have been studied in mice
with NER defects. Treatment with antioxidants is assessed in
these mice.
XP cells have been used as reagents to determine the
mechanism of action of chemotherapeutic agents. For
example, XP cells with defective TCR are hypersensitive to
killing by cisplatinum, but XPC cells with a global genome
repair defect have a normal response (Furuta et al., 2002).
This indicates that the TCR pathway has a role in the action
of platinum and suggests that tumors that are resistant
to platinum may have alterations in their TCR-related genes.
Interestingly, the use of XP cells determined that a toxin from
the sea squirt, ET743, was activated by this TCR machinery to
induce lethal DNA strand breaks (Takebayashi et al., 2001).
This agent is currently in clinical trials for cancer therapy.
Immune diversity is generated by hypermutability of Ig
variable genes in maturing B lymphocytes. The spectrum of
mutations in B cells from XP variant patients with defects in
the DNA polymerase Z were found to show a deficiency in
the frequency of A–T mutations and a concomitant rise in G–C
mutations. These data indicate that polymerase Z in involved
in generating mutations in Ig variable genes (Zeng et al.,
2001).
EPILOGUE
We are in the second decade of the twenty-first century. A
young child is taken out on the first sunny day of spring in a
modern umbrella stroller, but the child becomes irritable. By
the next morning, her skin becomes red and blistered,
necessitating a trip to the emergency room. The pediatrician
thinks this is a sun burn, but is concerned about how parents
could have let this happen. After a second episode, an astute
dermatologist recognizes acute burning on minimal sun
exposure, begins a work-up for photosensitivity disorders,
and instructs the parents to immediately start measures for
aggressive sun protection. The child will not burn again. We
have learned a great deal in the B140 years since Kaposi’s
description in 1874 (Hebra and Kaposi, 1874). We now know
that the skin changes of XP are the result of UV radiation
exposure. Once a diagnosis is made, the family can be
guided to sources of skin and eye protection (e.g., sun blocks,
protective clothing, window tinting), an easy-to-use UV
radiation meter, and instructional materials for the school,
and all of this may be facilitated through contact with patient
support groups that can be helpful in identifying resources for
the family (Tamura et al., 2010). We know many, but
probably not all, of the disease-causing genes. Genetic testing
may be available for confirmation of diagnosis not only in
patients but also in utero and for future pregnancy planning.
Vitamin D supplementation will prevent deficiency. Mon-
itoring for possible neurological involvement will permit
early detection and management (e.g., hearing aids). The
Americans with Disabilities Act (ADA) requires a safe, UV
radiation–protected school environment, and mandated
individualized educational plans assist in education.
This child may develop freckles and lentigines, but the
family should have the knowledge and tools to avoid most of
the damage that UV radiation can cause in XP. If a skin
cancer develops, advanced topical and surgical management
can provide a cure with minimal discomfort and cosmetic
alteration. Patients now can live healthy fulfilling lives well
into adulthood despite having many types of skin cancers (Oh
et al., 2011). Although we have reached this far, we still have
a long way to go. Many patients are unable or unwilling to
use extreme sun protection, and thus better methods are
needed. Genetic testing is not readily available. We do not
have effective intervention for neurological decline. In
addition, we often have too long a delay in diagnosis.
Individuals who do not have extreme sun sensitivity may not
be diagnosed early, leading to substantial sun damage at a
young age. Although all XP patients are at high risk for the
development of skin cancer, we do not understand why some
patients burn and others just freckle. We do not have a
method to reverse the damage. Also, why don’t patients with
TTD who have photosensitivity and abnormal NER develop
skin cancer? While we can diagnose, treat, prevent damage
and understand some of the pathophysiological mechanisms
in XP patients, there is still much more to learn.
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